A first-of-its-kind Human Papillomavirus (HPV) self-collection screening pilot program was launched on November 20, 2024, in Texas, aimed at improving cervical cancer screening in underserved communities. The study is being conducted at Su Clinica, a Federally Qualified Health Center, in collaboration with researchers at The University of Texas MD Anderson Cancer Center.
This initiative utilizes the BD Onclarity™ HPV Assay, which received U.S. Food and Drug Administration (FDA) approval earlier this year for HPV self-collection screening in healthcare settings. The study will evaluate the implementation and effectiveness of self-collected HPV testing in a real-world environment.
The program seeks to identify challenges and solutions for cervical cancer screening in communities with limited healthcare resources, ultimately aiming to reduce cervical cancer rates and disparities nationwide. The study is supported by a $2.5 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.